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A B S T R A C T
Osteoarthritis (OA) is a leading cause of disability worldwide. Clinical practice guidelines (CPGs) have
been developed to facilitate improved OA management. Scientiﬁc communities worldwide have
proposed CPGs for OA treatment. Despite the number of highly prominent guidelines available and their
remarkable consistency, their uptake has been suboptimal. Possibly because of the multitude of barriers
related to the implementation of CPGs. For example, different guidelines show contradictions, some lack
evidence, and they lack a hierarchy or tools to facilitate their translation and application. Also, the
guidelines do not acknowledge the effect of comorbidities on choosing the treatments. Finally, poor
integration of multidisciplinary services within and across healthcare settings is a major barrier to the
effective implementation of management guidelines. Here we describe the main problems related to the
OA guidelines and some solutions so as to offer some guidance on the elaboration of future CPGs and
their implementation in primary care.




Several international or domestic scientiﬁc groups have focused
on the need to improve the management of osteoarthritis (OA)
because OA is a leading cause of disability worldwide [1], it has a
high and increasing prevalence [2] and it is a chronic and incurable
disease [3]. Consequently, OA is associated with an extremely high
economic burden and is considered a priority problem for public
health internationally [4].
Clinical practice guidelines (CPGs) have been published to
improve OA management. CPGs are deﬁned as a structured set of
recommendations informed by a systematic review of the most
relevant evidence available. The guidelines aim to guide clinicians
in selecting the best care, taking into account the beneﬁts and
harms of therapies and the strength of the recommendations
appraised [5]. According to Lim and Doherty [6] the 3 main types of
evidence to guide clinical decision-making are research evidence,
expert opinion or experience, and patient opinion or acceptability.* Corresponding author. Royal North Shore Hospital, Rheumatology Department,
7C–Clinical Administration, Reserve Rd, St. Leonards, NSW 2065, Sydney, Australia.
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Scientiﬁc communities around the world have proposed CPGs
for OA treatment. The leading groups are the American Academy of
Orthopaedic Surgeons (AAOS) [7], European League Against
Rheumatism (EULAR) [8], US National Institute for Health and
Care Excellence (NICE) [9], OA Research Society International
(OARSI) [10] and American College of Rheumatology (ACR)
[11]. The guidelines differ in the joints considered (knee, hip
and/or hand) and the types of treatments proposed (pharmaco-
logical, nonpharmacological, nonsurgical and general). Despite the
multitude of available robust guidelines, their uptake has been
suboptimal [12].
To offer some guidance on the elaboration of future CPGs, we
need to examine the main limitations of OA guidelines and their
solutions. Thus, the aim of this article is to provide a critical
analysis of OA CPGs, barriers to implementation and possible
solutions.
2. Background
Efforts have been made to identify the reasons for the continual
gap between the CPG recommendations and clinical practice. A
systematic review of recommendations and guidelines for the
Table 1
Problems and solutions related to uptake of clinical practice guidelines (CPGs) for osteoarthritis (OA) management.
Problems Solutions
Literature limitation
Poor evidence of RCTs speciﬁc for hip OA
Poor evidence of therapies for patients with comorbidities
Contradictory information about some therapies that
lead to contradictory recommendations among
guidelines
Literature limitation
RCTs speciﬁc for hip OA
Systematic review and meta-analysis of controversy therapies
Inclusion of patients with comorbidities in RCTs to better represent clinical scenarios
Studies to test cost-effectiveness of CPG recommendations in different models of care
External limitation
Lack of time of GP to see patients
Resistance of patients to lifestyle changes
Lack of skills of some physicians
Limited access of patients to other health professionals
Patients beliefs
Inefﬁcient referral process
Inadequate model of care to implement CPGs
Poor integration of multidisciplinary settings
External limitation
More time for GPs to see patients
Effective multidisciplinary teams
Accredited training courses for GPs
Development of an efﬁcacious model of care that allows CPGs implementation
CPGs limitations
Absence of standardized methodology
Poor recommendation description
Illogical format for presentation of recommendations
Poor information about management of OA with
comorbidities
Disease driven guidelines
Absence of economic aspects of recommendations
CPGs limitations
Guide future research in order to increase research value and decrease waste with redundant work
Development of tools to aid communication with patient
Flowchart, algorithm or single page check-list to translate CPGs
Standardise CPG development to allow trustworthy and transparent guidelines
Develop patient driven CPGs rather than disease driven
Include cost-conscious aspects of each recommendation
Structured and logical presentation of recommendations
Detailed description of recommendations including, prescription, dosage and clinical scenario
RCT: randomized controlled trial; GP: general practitioner.
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dissemination and implementation [13]. The knowledge about the
speciﬁc issues is essential for developing solutions. Thus, we
organised this paper by these issues. Table 1 summarises the main
problems and solutions, which were based on the referenced
articles and the authors’ knowledge.
3. Target joint
Most CPGs are directed toward knee and hip OA; however, some
recommendations are often speciﬁc to knee OA and extrapolated to
hip OA. As noted by Bennell and Hinman [14], some ﬁndings
cannot be directly translated to hip OA because of differences in
biomechanics, impairments, rapidity of OA progression and risk
factors. Therefore, the extrapolated recommendations are mainly
based on expert opinion. This fact indicates limited evidence for
the management of hip OA.
4. Contradictions among CPG recommendations
Some recommendations are contradictory, which raises confu-
sion and debate about their validity. As an example, the
recommendation for intra-articular hyaluronic acid therapy is
inconsistent among guidelines. A recent study [15] indicated that
the reason for this discrepancy is the variable methodology used in
CPG development. The authors asserted that only a standard and
appropriate methodology for developing OA CPGs will prevent
conﬂicting recommendations. Other areas of inconsistency are the
use of acupuncture, knee braces, heel wedges, intra-articular
hyaluronan, glucosamine or chondroitin [13] and balneotherapy
[16]. A clear message must be transmitted to clinicians because the
uncertainty in advice about therapy prevents the most appropriate
decisions being made.
5. Transparency of CPGs
Nonstandardized CPG development results in substantial
variation in clinical practice recommendations. With this aim,the US National Academy of Medicine created the Committee on
Standards for Developing Trustworthy Clinical Practice Guidelines
[5]. The committee developed 8 standards involving: 1) esta-
blishing transparency, 2) management of conﬂict of interest, 3)
composition of CPG development groups, 4) systematic review
intersection, 5) establishing an evidence base for and rating the
strength of recommendations, 6) articulation of recommendations,
7) external review and 8) updating. The objective of these
standards is to increase the quality and trustworthiness of CPGs.
The committee believes that if adopted by guidelines developers,
the standards will improve healthcare quality and patient
outcomes [5]. One of the major problems today is probably the
management of conﬂict of interest. As is usual, the best experts
have many such conﬂicts, so rating the strength of recommenda-
tions by high-level experts with no conﬂicts seems challenging.
6. End users
CPG recommendations are directed predominantly to primary
care, so the general practitioner (GP) typically represents the main
end user. Therefore, the needs of GPs should be determined so that
they are correctly addressed. A survey involving GPs identiﬁed that
achieving adequate pain control was the most frequently cited
challenge in OA management, followed by lack of time and
encouraging patients to make lifestyle changes [17]. Solutions
identiﬁed by GPs included more time to see patients, collaboration
with a specialist team, a need for improved tools to aid patient
communications about risk, accredited training courses for GPs
and more staff and resources [17]. Another study explored GP
attitudes towards CPGs and found the need for shorter CPG
formats, ﬂowcharts or algorithms, and single-page checklists
[18]. Knowing GP preferences is an important strategy to
accurately target this population.
7. Tools for implementation
Guidelines must be offered in a user-friendly format to facilitate
adherence. In their last iteration, the ACR and OARSI guidelines
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based medicine to daily practice [10,11]. The European Society for
Clinical and Economic Aspects of Osteoporosis and Osteoarthritis
(ESCEO) proposed a treatment algorithm including a core set of
treatments, prioritizing different interventions taking into account
the presence of comorbidities, and patient symptoms. This paper
was the ﬁrst effort to produce a detailed algorithm to guide
physicians through the different steps of treatment for an
individual patient [19]. Considering the short time that GPs have
to see patients, algorithms can quickly and easily guide clinicians
and patients to adopt the best care possible.
8. Barriers to implementation
Recommendations must be clear and with an action implied to
allow their correct implementation. Loyola-Sanchez et al. [20]
identiﬁed the barriers to implementing a guideline for OA
management in Mexico at the local primary care level. Many of
the barriers identiﬁed are common to worldwide. For example, the
settings in which several recommendations should be applied are
not described and how the recommendations are presented lacks
sequential logic. The authors suggested that guidelines should
provide detailed statements, informing the advised prescription,
dosage and clinical scenario for each recommendation. Problems
with clarity and conciseness negatively affect the application
within primary care practice.
Implementation failure it is not only the fault of CPGs. As
identiﬁed by Loyola-Sanchez et al. [19], 3 main types of external
barriers are:
 individual factors (limitations of physician skills and patient
beliefs);
 organizational factors (insufﬁcient time and inefﬁcient referral
processes);
 system-related factors (inadequate model of care).
Therefore, effective CPG implementation requires complex
changes that involve more than just content.
9. Multidisciplinary approach
Management guidelines relate to the healthcare provided by a
variety of different health professionals. Brand and Cox [21]
investigated the barriers to effective implementation of best-
practice recommendations for nonsurgical management of OA of
the hip and knee. The authors identiﬁed poor integration of
multidisciplinary settings. Patient access to other health pro-
fessionals and specialists can be an issue in that time pressures are
a frequent barrier, which prevents implementation of the best care.
The authors concluded that imposing the CPG recommendations
within a model of care that does not support them is likely to result
in failure of implementation. With this in mind, the Chronic
Osteoarthritis Management Initiative (COAMI) aims to improve
current OA management by developing a comprehensive and
evidence-based model of care [13]. Adherence to guidelines is
feasible only with a multidisciplinary approach.
10. Economic aspects
Not considering local socioeconomic and political factors may
also result in failure to implement CPGs. To allow the assessment of
economic aspects, the ESCEO [22] aims to provide evidence-based
recommendations with a cost-conscious awareness. Future CPGs
should incorporate these ﬁndings, providing more data for the best
decision-making. Economic evaluation allows for the appropriate
allocation of health resources.There is a need to assess the feasibility and the effect of CPG
implementation at the primary care level. With this in mind, an
ongoing study with a published protocol is assessing the clinical
and cost-effectiveness of implementing the core recommenda-
tions from NICE [23]. More studies should investigate whether the
CPG recommendations can be accomplished and under what
conditions.
11. Research prioritization
Guidelines have an important role in identifying whether a
therapy has limited or contradictory evidence or if it is already well
established. CPGs must guide the path of future research via a clear
indication of literature gaps. Therefore, detailed recommendations
instead of general guidance should be provided, which might
make correct implementation difﬁcult. Research value should be
increased and waste with redundant work decreased.
12. Disease-driven rather than patient-driven
Guidelines should become patient-focused rather than disease-
driven. Current guidelines are challenging to apply to patients with
multiple conditions and different phenotypes. The recommenda-
tions do not consider whether a comorbidity is present. Therefore,
CPGs represent a scenario that is not compatible with clinical
practice. In fact, CPGs are only a reﬂection of the available
literature. Often, patients with comorbidities or with a speciﬁc
phenotype are excluded from many randomised clinical trials. In
their last iteration, the OARSI guidelines introduced for the ﬁrst
time the notion of comorbidities to improve the personalization of
treatment.
It is important to remember that patient well-being is the
research priority, so future clinical trials should consider study
criteria that correctly reﬂect clinical practice.
13. Conclusions
CPGs must be joint-speciﬁc and disease-driven rather than
patient-driven, their development should be mindful of contra-
dictions among recommendations, and they should adopt criteria
that allow for transparency and beneﬁt end users by providing
tools for implementation. CPGs should also recognise the barriers
to implementation in the current model of care. They must
encourage a multidisciplinary approach and provide the economic
aspects of treatments. An unexplored role is to guide future
research so as to increase research value and decrease waste with
redundant work.
CPGs per se are not enough to improve the healthcare
management of OA. The guidelines can be enhanced, but we must
consider the local context and barriers to implementation and the
complexity of changes that must occur before their implementa-
tion.
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